In Q1 2026, TuHURA Biosciences commenced pivotal Phase 3 clinical trials for its lead immuno-oncology candidate, IFx-2.0, targeted at advanced cutaneous melanoma and Merkel cell carcinoma. The company’s acquisition of Kineta in mid-2025 adds depth to its therapeutic pipeline and technological capabilities. Despite no product revenue and ongoing net losses, TuHURA secured a $50 million revolving credit facility in April 2026 to underwrite clinical development. The firm’s position within the orphan drug space offers regulatory and market exclusivity benefits, but growth remains contingent on clinical outcomes and capital market access.